Fig. 5: Impact of C@MSN-P-A8 on BMM osteoclast-specific gene expression and the NF-κB and MAPK signaling pathways.
From: Bone-targeted celastrol nanocarrier suppresses osteoclastogenesis in postmenopausal osteoporosis
A RT-qPCR analysis of osteoclast-specific gene expression levels of CTSK, TRAP, and CTR mRNA in each group. B Western blot assessment of the expression levels of p-IκBα and p-p65 proteins in the NF-κB pathway in each group of cells. C Western blot analysis of the expression levels of p-JNK, p-ERK, and p-p38 proteins in the MAPK pathway in each group of cells. D Western blot analysis of the protein expression levels of c-fos and NFATc1 in each group of cells. ‘ns’ indicates no significant difference between the two groups, * represents comparison between the two groups, *P < 0.05, **P < 0.01, ***P < 0.001. The cell experiments were conducted in triplicate.
